交银国际(0.27,-0.01,-3.57%)发布研报称,维持先声药业(12.22,-0.28,-2.24%)(02096)“买入”评级,目标价14.3港元,维持行业重点推荐。上调对该公司2025-2027年纯利预测6-11%。看好短期内达成更多出海交易的潜力,可重点关注CDH6、CDH17等近期关注度较高的标靶。交银国际指,ASCO2025大会上,公司肿瘤管线共有18篇研究获展示。建议重点关注:...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.